Dose adjustment rate of inhaled drugs containing glucocorticoid
One hundred twenty‐five participants were treated with inhaled drugs containing glucocorticoid during the 6 months of follow‐up, comprising 54 participants in the DG and 71 in the NDG, and there was no significant difference in use of these drugs between the two groups (The dose adjustment rate of inhaled drugs containing glucocorticoid between doxophylline group and non‐doxophylline group.For the neutrophilic subtype, 25 participants in the DG and 35 in the NDG were treated with inhaled drugs containing glucocorticoids. There was no significant difference in the dose adjustment rate between the two groups in the first month (For the eosinophilic subtype, 10 participants in the DG and 11 in the NDG were treated with inhaled drugs containing glucocorticoids. There was no significant difference in the dose adjustment rate between the two groups in the first‐ or third‐month follow‐ups (For the mixed granulocytic subtype, 18 participants in the DG and 26 in the NDG were treated with inhaled drugs containing glucocorticoids. However, there were no significant differences in the dose adjustment rate among this subtype during the 6‐month follow‐up period (The dose adjustment rate of inhaled drugs containing glucocorticoid of clinical phenotypes.